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Xenotransplantation is considered to be a solution for the human donor shortage. However, there is a 
potential risk of transmitting animal infections from the transplanted organ. The known transmissibility and 
clinical significance of human cytomegalovirus (HCMV) infection after allotransplantation led us to evaluate 
whether baboon cytomegalovirus (BCMV) transmission could occur after a baboon-to-human liver xenotrans-
plant. We examined serial blood samples from a baboon liver recipient and isolated replication-competent 
CMV-Iike agents on days 29, 36, and 42 after xenotransplantation. BCMV and HCMV DNAs were detected in 
the day 29 isolate, while only HCMV DNA was detected in the other isolates. This is the first report of detecting 
a replication-competent virus from a source animal after xenotransplantation and is a concern with regard to 
potential zoonotic transmission to others. 
Solid organ transplantation is an established treatment for a 
number of end-stage organ disorders. However, its use is lim-
ited by the number of available human donors. This shortage 
has been a key impetus for the use of organs from animals, 
including baboons, for xenotransplantation (3, 10). A major 
concern with xenotransplantation is that infectious organisms 
can be transmitted from the animal donor to the recipient of 
the organ. This is particularly important for cytomegalovirus 
(CMY), since transmission of human CMY (HCMY) after 
allotransplantation can lead to serious disease (2, 4). While 
CMY is considered to be species specific, we previously 
showed that baboon CMY (BCMY) can replicate on human 
fibroblasts in vitro (6). In addition, there is a high seropreva-
lence of BCMY in adult baboon populations (7, 12). Accord-
ingly, we investigated whether BCMY could be transmitted via 
baboon-to-human liver xenotransplantation. 
(This work was presented in part at the 39th Interscicnce 
Conference 011 Antimicrobial Agents and Chcmotherapy, San 
Francisco, Calif., 26-29 September 1999). 
MATERIALS AND METHODS 
A 3:-;-year-old man with cnd-stage liver disease secondary to infection with 
hepatitis B virus received a baboon liver scnotransplanl as previously described 
(9). The patient was known to be infected with human immunodeficiency virus 
and hau undergone a splenectomy following a motor vehicle accident. The 
patient \vas ser{Frn~itivc rnr 1 JCMV hefon: transplantation hut did not have 
active HeMV disease. He received a liver from II haboon that was scropn~itive 
for BCMV. Prophxlaxis agaInst HCMV consisted of ganciclovir administered 
intravenously from () to 1:-;: days after tral1splap1:JI;nn. G:lIlciclovir acimini-;tral;nl1 
wa:.; reinstituted Oil d(lV 3(1 ill rC~p{ln"iD 1n rtDsl~rK l.'..,ophag;t;s, and (l viell culture 
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positive for CMV from the blood and was continued until Ihe patient's death 70 
days after xenOlransplantation. Acute hemorrhage of the brain secondary to 
disseminated aspergillus infection was seen at autopsy. There was no pathologic 
evidence of active CMV disease at the time of death. 
The donor animal was an adult male baboon (Papio anubis) born and raised in 
captivity in the United States. It was screened for known human and primate 
microbial pathogens by available serologic assays. In addition, bacterial and viral 
cultures were obtained from the blood, urine, throat, and stool prior to trans-
plantation and at autopsy. Parasitic infestation was evaluated by examination of 
the stool and peripheral blood smears, Serial tuberculin skin testing was per-
formed to evaluate for Mvcobacterium tuberculosis. Samples from the human 
patient's blood. urine, and throat were obtained prior to transplantation and 
every I to 2 weeks after transplantation. In addition. biopsy and autopsy speci-
mens were subjected to viral culturing. 
PCR analyses. PCR analysis for BCMV DNA was performed using primers 
specific for the major immediate-early (MIE) gene and consisted of 5'-TACGT 
CATTGGTACCCfCC-3' (LGHI966) (pmvidcd hy Gary Havward) and 3'-TA 
GTACAlTGGCAGTACfCC-S' (BCMV002). The amplified product was 249 
bp. Amplifications were performed in a thermal cvcler (Techne. Princeton. N.J.) 
under the following conditions: one cycle at 94°C for 5 min followed by 40 cycles 
of 95T for I min. S2°C for 30 s. and 72°C for 2 min. PCR products were sepa-
rated on 2'i" agarose gels and visualized hy ethidium hromide staining. Primer 
sequences for PCR detecti(iJl) of HCMV DNA (specific for the HCMV MIE 
gene) were 5'-CCACAATT CTGAGGACAGAGG-3' (CMVA) and 3'-CGG 
GGGCATGTACCAGTAG AT.)' (CMVB), The amplified product was 377 
hp. Thermal cycler conditions for HCMV amplification were the following: 40 
cycles of 92°C for J min. 55°C for I min. and 71°C for 1.25 min followed hy a final 
extension at 72°C for 7 min. PCRs were carried out in a 50'111 total volume 
containing PCR Supermix (Gihco BRL Life Technologies. Grand Island. NY), 
0.25 I1g of each oligonucleotide primer. and JOO to 400 I1g of total DNA. 
Extractions from paraffin-emhedded tissue were also subjected by PCR analysis 
(0 detection of glyceraldehyde-3-phosphate dehydrogenase as previously de-
scrihed to ensure adequate extraction of DNA and the ahsence (If PCR inhibitors. 
OvernIght hybridization with ,oP-labeled species-specific internal probes was per-
formed '" previouslv described (6) with the exception that for HCMV MIE. the 
lllternal probe sequence was S'-TCATCTGACTl"CTCG-3' (CMVP) and hy-
hriJizatioll was done <.It 41°C. 
Ganciclovir plaque reduclion assays were performed as follows. Confluent 
layers of MRC5 cells (American Type Culture Collection. Manassas, Va.) in 
K:D~l--yycll F,]kon tis:-.uc culturl.'. pL-IlC'- (Fil.;hcr Scit'lltiflc Co, milt~hllrghI Pa.) were 
inocula(ed in triplicate with IOf) 1"1 (If each virus that was prcuetcrmined to 
contain approximately .'in PFU. Virus was allowed to adsorb to fibroblasts under 
, 
I' . I,,' 
f' 
l! 
2826 MICHAELS ET AL. 
Patimt Samples 
::t ~ ::c (") ,.., ,.., 
A a:: g. (") (") (") ~ <: Eo E. Eo f: E ~ ~ ~ ~ tl:I ~ ~ '" (") (") c. 
'" 
Q. 
~ e. ~ ~ 'tl (") ( ) e-O) ,.., 
" ~ r ~ ~ ~ ~ t:i Q tl !l' " ~ fl' ~K Q 9- ~ fl' t; 
" 
'< 
.". t; > ~ i 5 10 to '" ... .. ~ "" '0 '" ... ... 
248 BP 
4 5 6 8 9 
Patient Samples 
~
B (") (") := n n (') . . :. ~ ~ ;; ;; ~ . ;: :. • .. .. .. ~ n til n n n ~ ~ ... ~ ~ ~ 
" '" ~ .. I;:J t:> n ~ ~ .. 2-~ .. ~ Z ~ ~ '" ::. ~ > 
'" '" 
377BP 
8 
FIG. 1. (A) PCR amplification of DNA samples with BCMY-spe-
cific primers. The upper panel shows PCR products electrophoresed 
on a 2% agarose gel and visualized with ethidium bromide. The lower 
panel is a DNA blot hybridization of PCR products using a 32P-labeled 
oligonucleotide probe specific for BCMY DNA. Lane 1, no DNA; lane 
2, DNA from unrelated HCMY (negative control); lane 3, BCMY iso-
lated from an unrelated baboon (positive control); lane 4, BCMY iso-
lated from the oropharynx of the donor animal prior to transplanta-
tion; lane 5, patient PBL from day 29; lane 6, CMY isolate from patient 
PBL from day 29; lane 7, CMY isolate from patient PBL from day 36; 
lane 8, CMY isolate from patient PBL from day 42; lane 9, unrelated 
HCMY isolate (negative control), (B) PCR amplification of DNA 
samples with HCMV-specific primers. The upper panel shows PCR 
products electrophoresed on a 2% agarose gel and visualized with 
ethidium bromide. The lower panel is a DNA blot hybridization of 
PCR products using a .'2P-labeled oligonucleotide probe specific for 
HCMY DNA. Lane I, no DNA; lane 2, DNA from unrelated BCMV 
(negative control); lane 3, laboratory HCMV strain AD 169 (positive 
control); lane 4, patient PBL from day 29: lane 5, CMV isolate from 
patient PBL from day 2Y; lane 6, CMV isolate from patient PBL from 
day 3(,: lane 7, CMV isolate from patient PBL fWIll day 42: lalle C;, 
unn:laLcd IICMV clinical isulatc Enegaliv~ control): lanc Ii, l3C;\1V 
isolated from the oropharynx of the donor ~lflimal prior to tr;lIlSpliln-
lalion. 
cEFndition~ of ,-1.,7°C and )'i CEF~ for l)() mill. Wells \vere overlaid (1.5 mliwl'll) 
with fl1~girlll lDollsislill~ (d" iI \:1 Illi.\{un.: uf (U-;I( ScaPl;u.jllc dt.:dH):--C fc~~lC 
Bioproliucts, Rockland, IViaine) and mouilied Eagle ll1euiul11 «jih,'" BRL Life 
Technologies) slIJlrlcmentcd with ~{~rIK serum supreme EBiElthitt:KK~crK \Valkers-
ville. Md.) and 1.-glutamil1l'. Overlay media containcd media ;-.uppIl'IlH':rltL'd \\'ill1 
gal1ciclovir C()[lCt'ntratinlr, l'llllging from I to SO f...LM: six DvyK:ll~ l"1 .... cl'i\ni 111L'llld 
without gancicltwir. Plates WL'rC allowed tu gel :It t1l11hiL'l1lIClllfKT;IInH' ;Ind Ihell 
J. VIRUL. 
were placed in a 37°C humiuified incubator with 5% CO, for 10 Jays. The S(n 
inhihilllry ~lllc-":gltralilF1l ~fCRuF was oetL:rmined by measuring tht gancidovir 
conc~ntration that curr~latiDu \villl a 5W:; __ feliuctiun in the number dr viral 
plaques compared with the number of plaques in the absence of ganciciovir. 
RESULTS 
BCMV was isolated from a throat swab that was obtained 
from the baboon donor animal 4 days before transplantation; 
all other specimens collected from the animal at the time of 
transplantation, including cultures obtained from the liver, 
blood, spleen, lymph node, and lung, were negative for viruses. 
A total of 41 specimens were obtained from the recipient for 
viral culture: blood leukocytes (buffy coat) (/1 = 12), throat 
(/1 = 9), urine (/1 = 6), and body tissue (n = 14). Virus with a 
cytopathic effect characteristic of CMV was isolateu from hu-
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FIG. 2. (A) PCR amplification of DNA samples with BCMV-spe-
cific primers and probe. The PCR product was electrophoresed on a 
O~D; <lgarose gel and transferred fur DNA blot hybriuiz<ltion using a 
,oP-labeled oligonucleutiue probe specific fur BCMV DNA. Lanes I 
and 2 have BCMV positive controls. Lane 3. purified plaque-I frnm 
day 29 virlls: lane 4, purified plaque-::! from day 2() virus: lam: 5. p_::! 
passage of purified plaque-2; lane 6. purified pl<llJuc-3 from day 29 
virus: lanc 7, purified playuc-4; lanes Hand ti. HCMV negative con-
trols. (B) PCR amplification uf DNA samples with HCMY-specific 
primers and probe. PCR product was electrophoreseci on a 2"{ <lg<lrose 
f!el and transferred for DNA blot hybridiziltJ()n using a l';P-I;tbeled 
"Ii,l!llllucicotide probe specific for I-ICMV 01'1.\, Line t 11\1 DNA: 1;lnc 
2, BCMV negative control: lanc 3, HCMV positive control: Ialle 4, 
BCMV nega~ive control; lane 5. purified plaque-I from day 2') virus; 
lanc 6, pUrified plaque-2 fron~ day 2fJ virus: lane 7, 1'-2 passage of 
jlllrlilcd plaque-2: lane I~K punhcd pl'lquc-3 frolll day 29 virlls: lane Ii, 
purified plaque-4: lanes 1(\ and 11.1[( '''1V p"sllivc clll1trols. 
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A 
Mit qAqfddqDgE:D~D AA(3TCA':'TAT TAATACjTATT G./I.TGi '"["3 r:' (.:.vJ-jTC;GC: C (' 
eCMVI TTGGTG(,(: AAGT<::.t\CTAT T AATAGTATT GAT<n'/.' D<;:Dl::gl~ CAA_GTC';GG C C 
BCMV:,: TATTGGTGC(, AAdqCACqAqqAAqAdqAqqEiAqD~;qD;D:D/-KDqrIED (":'JI •• I> .. <3TGGC T C' 
f'al.lml GTGCC' ? .... AGTCACTAT TAATAGTATT dAqlqj:;g":DqD~D-D D~DAAEPqddE:; c: , ..... 
Donor '3T'3''':"'(' _'U'.,3T('AC'T J. T T ." ........ TAGT.\ 'IT I~;~ '. qE~:qK"DK :1":; :' D~DKrKADgqdI~jE=-; C 
:'1.11£ AqqfAD~Dq<KgDI-_;D-D:: ATTGACGTCA AqAI~EjC;EjlgCDEj qtgDI-iD:jmu~E:D:Add ATl ... TGAATGG 
llCl\'l\Tl ATITA·.;'i.'GG':' }.TTGACG1\':;A ATAGGGGI.3C(i T(:;(.il,:,iJ-\JI..CJV}G ATATGAATGG 
RCM"1 .fl. TTTACTCiG:' ATTGACGTCA ATAGGGG(3CGT('GGJ'!.AC}.J:'iG J\TATGAATG'-:::; 
Patient A TIT ACTGGC A TTGACGTCA A TAGGGGGC"-:; qID-~ddAACkgCi ATATGAATGG 
Donor ATTTACTGGC ATIGACGTCA ATAGGGGGCG TGGGA.ACAGG ATATG1.J..TGG 
IvlI[ dCAAqI-jAC;E~DC ACCCE~DAfqdA CdqC<~~KAqddq AG(jTG'3T(,CC TATTC;/".(::-'GTr' 
HCMVl dCAm_qdKu~IK:iyIu: ACCCCATT'3A E~dq~Mqddq AGGTGGTCCC TATTGACGTC' 
BCMs~ GC'AATGAGC'C ACCCCATTGA CGTCAATGGT AGGTGGTCCC TATTGACGTC 
P"dt.Umt G(::'A.i<.TGAGCC AC'CCCATTGA CGTCAATGGT AGGTGGTCCC TATT.3ACGTC 
Donor G::AATGAGCC ACCCCA'ITGA CGTCAA TGGT AGGTGGTCCC TA DqfDdKn~CdqC 
MIE AATGGGAGGT CC C AATGACG TATA T GGAAC CCTATATATG GCCATTCATT 
BCMVl AATGGGAGGT CC C AATGACG TATA C GGAAC CCTATATATGGCCATTCATI 
BCMVl AATGGGAGGT CC L AATGACG TATA C GGAAC CCTATATATG GCCATTCATT 
Pati",' AATGGGAGGTCC C AATGACGTATA C GGAACCCTATATATGGCCATTCATT 
DUl\{lI i'. .... Il..TGG(::;AGc:::T CC C' AJ..T'3ACG qK~Kq;_ C GGAA(' CCT • KDK~qAqAqd G'="::ATTC:/'.T'? 
B 
BCMV TA Cd1D~qqddq AnO£~ 
HCMV CC dCC~KCdAC C~~ 
BCMV TATTAT.L.ATG AATGGCCATA TMAGGGT":'C CATATATCG'I CM'TGGGACC 
HCMV !dACdqC~q AATG ••• ~d TATGTTCCCA q~dq~CdCC ~AdddACq 
HeMV' !KC~ ~A~ •. ~C~C~ bCA!Kqd~dq £A}yq~qd 
HCMV !q~ ~~dq ~dq~q~ £dd!~qd £CCKAKCqq~dC 
HCMV GCTCATTGCC CATTCATATC CTGTTCCCAC Ga::CCCTATT GJ\CGTCAATG 
HCMV AG!ACA!CAA GTc;!ATC!!A qdCCAAdq~ GO::CCCTATT GFlCGTCAATG 
Bcm CD£A~ ~A£D!Dqdd ~d~C·Aq£K~K ~qACq~q!!KK ATAGTGAC 
HCMV A£~ ~dp:C!§n ~q~qdC£C ~dqAC!!d~CCq TAT§:G;AC 
BCMV !!,GG£ACSAA qAq~ TGG£AGTACT C~qbAC 
HCMV !!TC£TA£TT dd~ CTA£GTATTA dqCAqC~Cq 
FIG. 3. (A) DNA sequences of PCR amplification products from 
BCMV MIE plasmid clone (MIE); unrelated BCMV isolate 1 (BCMV1); 
unrelated BCMV isolate 2 (BCMV2); BCMV isolate from day 29 from 
the patient (Patient); BCMV isolate from the donor animal's throat 4 
days prior to transplantation (Donor). Boxes indicate the locations of 
DNA sequences that vary among the different strains. Sequence align-
ments were performed using the program Pileup from the GCG Se-
quence Analysis Package. (B) Comparison of the DNA sequences of 
the MIE gene from the amplified product of the BCMV plasmid clone 
and the HCMV AD169 strain. Sequence alignment was performed 
using the program Bestfit from the GCG Sequence Analysis Package. 
man foreskin fibroblasts and MRC5 human fetal lung fibro-
blast cultures that were inoculated with the patient's peripheral 
blood leukocytes (PBL) obtaincd on days 29,36, and 42 after 
transplantation. A CMV-Iike virus was also isolatcd from a 
culture of a duodenal biopsy specimen obtained 54 days after 
transplantation; however, this virus isolate was not available 
for further study. 
To determine the identity of the CMV isolates, DNA was 
extracted from the three PBL culture isolates as well as from 
the original PBL cryopreserved on day 29 and subjected to 
PCR analysis for both BCMV and HCMV DNA (Fig. I). The 
DNA isolated from the cell culture isolate of day 29 PBLs 
showed amplification with primers directed against the BCMV 
MlE gene (Fig_ lA lane 6) and with those directed against the 
HCMV MIE gene (Fig. I B. lane 5). Hybridization with '2p_ 
radiolabekd internal oligonucleotide probes cunfirmed the 
identity of these products. Serial passage uf this isolate, for up 
to flve times in human foreskin fihrohlast, and MRC5 cells, 
continued to yield positive PCR results with the BCMV -spe-
cific primers (data not shown). Plaque purification of virus was 
likewise performed. Positive PCR results were found from four 
purified plaques lIsing BCMV-specific primers and probes but 
not with HCMV-specific primers or probes (Fig. 2)_ An aliquot 
of the original day ~EF PBL specimen was also positive by PCR 
for BCMV DNA and HCMV DNA with a ->2P-labeled probe 
(Fig_ I A. lane ), and Fig. I B, lane 4). Insufficient sample 
material was available to repeat these studies, and original 
PBL samples from the other two isolates (days 36 and 42) were 
not Cl\aJlablc. 
DNA sequencing of the PCR products conlirmed the pres-
ence of BCMV in the patient's CMV isolate on day 29 post-
xenotransplantation. The PCR products from the donor's 
BCMV isolate, the patient"s day ~lg CMV isolate, three other 
unrelated BCMV isolates, and a BCMV MIE plasmid clone 
(kindly provided by Gary Hayward) were separately sequenced 
two to four times. Comparison of the different DNA sequences 
demonstrated 98 to 100% homology (Fig. 3A). Comparison of 
the BCMV MIE plasmid clone sequence with the homologous 
region in HCMV revealed a significantly lower 50% homology 
(Fig. 3B). These results, in conjunction with the PCR results, 
confirm the presence of BCMV in the patient's CMV isolate 
from 29 days after transplantation. 
The replication-competent BCMV appeared in the periph-
eral blood of the xenotransplant recipient 10 days after the 
cessation of ganciclovir therapy and disappeared from the 
blood following the reinitiation of therapy on day 30 (Fig. lA, 
lanes 6 to 8). In contrast, HCMV continued to be detected in 
the blood (Fig. 1 B, lanes 5 to 7). These results suggest that the 
patient's BCMV isolate is more susceptible to ganciclovir than 
his HCMV isolate. To test this hypothesis, ganciclovir suscep-
tibility was determined by plaque reduction assays on the pa-
tient's day 29 isolate (a mixture of BCMV and HCMV) and the 
day 42 isolate (HCMV alone) along with BCMV from an un-
related baboon. The results shown in Fig. 4 demonstrate that 
the lC50s of ganciclovir for BCMV from the unrelated baboon 
and the patient's day 29 isolate are significantly less than the 
ICslJ for the patient's day 42 HCMV isolate (1.14 ±: 0.622 M, 
2.4 ±: 0.38 M, and 7.2 ±: 0.91 M ganciclovir, respectively). 
10 
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FIG. 4_ Pla4uc rcducliun assay: IC511 of ganciclovir with standard 
deviation is shown for the control strain of BCMV, the CMV isolate 
from the patient from day 29. and the HCMV from the patient from 
day 42. Results are based on three different experiments, each using 
ganciclovir dilutions tested in triplicate. The numbers indicate molar 
concentrations. 
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DISCUSSION 
This is the first report of the isolation of a replication-
competent virus from a source animal in a patient who under-
went xenotransplantation. A previous report on the same re-
cipient found evidence by PCR of a simian foamy retrovirus in 
sites distant from the baboon liver (I). However. simian foamy 
virus could not be cultured from the patient, and the virus 
DNA was always found in conjunction with similar or grea\.er 
quantities of DNA from baboon mitochondria. Accordingl\ 
true infection of the patient with simian foamy virus could not 
be established. A recent report found porcine endogenous 
retrovirus to be transmitted across species in an immunosup-
pressed nonobese diabetic severe combined immunodeficiency 
mouse model (11). However, investigations of human recipi-
ents of porcine xenotransplant grafts failed to find evidence of 
porcine endogenous retrovirus transmission or other overt in-
fections from donor animals, although evidence of microchi-
merism was present for as long as 8.S years (8). 
We previously reported that BCMV replicates in human 
cells in culture (6). These results are confirmed in this study by 
the isolation and serial passage of the patient's BCMV isolate 
in human foreskin fibroblasts and MRC-S cells. The isolation 
of BCMV from the patient's PBL suggests that human cells 
were infected with the virus in vivo. Furthermore, replication 
competence was demonstrated by serial passages and plaque 
purification that separated BCMV from the primary isolate 
that contained both BCMV and HCMV. However, since mi-
crochimerism has been demonstrated in this patient's blood 
(9), it is also possible that baboon leukocytes, infected with 
BCMV, were circulating in peripheral blood and represent the 
source of BCMV in the day 29 PBL sample. Nonetheless, it is 
notable that replication-competent BCMV, capable of estab-
lishing a lytic infection in human cells in vitro, was present in 
the peripheral blood of a human 4 weeks after receipt of a 
baboon liver. 
BCMV was isolated only once from the patient's PBL (day 
29), while HCMV was isolated on two additional occasions 
(days 36 and 42). The BCMV isolation occurred while the 
patient was off intravenous ganciclovir therapy. The inability to 
recover BCMV on subsequent occasions, after reinitiation of 
antiviral therapy, almost certainly is attributable to the isolate's 
susceptibility to ganciclovir. The ICso for the day 29 isolate 
being in between the ICsII for the BCMV control and for 
HCMV isolated on day 42 is likely a secondary effect of the 
presence of both BCMV and HCMV on day 29. 
fn summary, BCMV was isolated from the peripheral blood 
J. VIROL. 
of a recipient of a baboon liver transplant 4 weeks after trans-
plantation and 10 days after discontinuation of prophylactic 
ganciclovir therapy. This is the first time that an infectious virus 
from a donor animal has been isolated from a recipient of a 
xenolransplant. In this case the BCMV was susceptible to 
ganciclovir and responded to treatment. However, the isola-
tion of the virus highlights the importance of potential cross-
species transmission of disease to the recipient. In addition, 
isolation of BCMV from the patient's blood represents a risk 
to others who might have accidental contact with the blood. 
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